What does biochemical recurrence of ovarian cancer mean?
In general, biochemical recurrence of ovarian cancer refers to a condition in which tumor marker levels rise during post-treatment monitoring of ovarian cancer patients, even though no obvious tumor recurrence or progression is yet detectable by imaging. If any discomfort occurs, immediate medical consultation and treatment are recommended. The detailed analysis is as follows:
Biochemical recurrence of ovarian cancer indicates that although conventional imaging tests have not revealed new tumor lesions, changes in biochemical markers—such as cancer antigen 125 (CA-125)—may suggest the presence of microscopic, undetectable residual disease. This situation typically requires more sensitive biochemical assays, such as CA-125 testing, to evaluate disease status. The mechanism behind biochemical recurrence may involve residual cancer cells or microscopic tumor deposits that gradually become active again after treatment, leading to elevated tumor marker levels. Although biochemical recurrence does not yet manifest as visible lesions on imaging, it may represent an early sign of tumor progression.
Therefore, close monitoring for biochemical recurrence in ovarian cancer is particularly important to enable timely intervention, and patients should actively cooperate with their physicians in managing treatment.